Researchers found that a new device called the Ceribell Delirium Monitor System has received a New Technology Add-on Payment (NTAP) from the U.S. Centers for Medicare & Medicaid Services (CMS). This payment, which can be up to $2,171 per eligible Medicare patient case, is intended to support the use of this innovative system in hospitals. The Ceribell device is the first FDA-cleared tool designed to help clinicians screen and monitor patients for delirium, a serious condition often seen in critically ill individuals.

This development is significant for anyone concerned about aging and cognitive health. Delirium can lead to longer hospital stays and worse outcomes for older adults, so having a reliable way to detect it early can improve patient care. The Ceribell system continuously analyzes brain activity through electroencephalograms (EEGs) and alerts healthcare providers when it detects patterns indicative of delirium. This capability can help ensure timely and effective treatment, potentially leading to better recovery outcomes for older patients.

The evidence supporting this system is still emerging. The NTAP approval follows the FDA’s clearance of the device in December 2025, which means it has been recognized for its potential benefits but is still in the early stages of widespread clinical use. While the initial findings are promising, it will take time to see how effectively the system can be integrated into routine hospital care and its long-term impact on patient outcomes.

For those interested in brain health, staying informed about advancements like the Ceribell system can be beneficial. While this technology may not be directly accessible to everyone yet, understanding its potential can help you advocate for better care options for yourself or loved ones in healthcare settings.

Source